Fadi T. Khasawneh, Ph.D.

Associate Professor (with tenure) and Chair, Pharmaceutical Sciences


Education

Ph.D., Pharmacology, University of Illinois at Chicago, Chicago, IL, USA May2007

B.S., Pharmacy (B.Pharm.), Jordan University of Science & Technology, JORDAN February1999

Professional and Academic Experience

Associate ProfessorSchool of Pharmacy, University of Texas at El Paso, El Paso, TX

(October 2016 - present)

Associate ProfessorCollege of Pharmacy, Western University of Health Sciences, Pomona, CA

(July 2013 - October 2016)

Assistant ProfessorCollege of Pharmacy, Western University of Health Sciences, Pomona, CA

(Feb 2008 - June 2013)

Associate Member Graduate College of Biomedical Sciences,Western University of Health

(Nov 2010-present)Sciences, Pomona, CA

Postdoctoral ResearchDepartment of Pharmacology, College of Medicine, The University of

AssociateIllinois at Chicago, Chicago, IL

(May 2007-Feb 2008)

Research AssistantDepartment of Pharmacology, College of Medicine, The University of

(Aug 2004- May 2007)Illinois at Chicago, Chicago, IL

Teaching AssistantDepartment of Pharmacology, College of Medicine, The University of

(Aug 2001- Jul 2005)Illinois at Chicago, Chicago, IL

  • In addition to other teaching-related activities, conducted medical pharmacology review sessions for Urban Health Program medical students for three years

Teaching AssistantCollege of Pharmacy, Jordan University of Science and Technology

(Oct 2000- Jun 2001)Irbid, Jordan

  • Taught the following instructional laboratories: Pharmacognosy, Analytical Chemistry I, Analytical Chemistry II, and Organic Chemistry.

Research AssistantCollege of Pharmacy, Jordan University of Science and Technology

(Jan 2000-Jan 2001)Irbid, Jordan

  • Conducted comprehensive quality control analysis for pharmaceutical products.
  • Applications included: Tablet Tests included disintegration, dissolution, hardness, uniformity, friability, and potency assays.

Hospital Pharmaceuticals Hikma Pharmaceutical Company

Specialist Amman, JORDAN

(Apr 1999 - May 2000)

InternDepartment of Pharmacy & Providence at Al-Hussein Medical

(Jun 1998 - Sep 1998)Center, Department of Royal Medical Services

Publications

Journal Publications (Peer-Reviewed)

  1. Khasawneh F.T., Huang J., Turek J., and Le Breton, G.C., “Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein”,J Biol Chem. 2006 Sep;281(37):26951-65
  2. Khasawneh F.T., Huang J., Mir F., Srinivasan S., Tiruppathi C., and Le Breton, G.C., “Characterization of Isoprostane Signaling: Evidence for a Unique Coordination Profile of 8-iso-PGF2α with the Thromboxane A2 Receptor, and Activation of a Separate cAMP-Dependent Inhibitory Pathway in Human Platelets”,Biochem Pharmacol. 2008 Jun;75(12):2301-15.
  3. Srinivasan S., Mir F., Huang J., Khasawneh F.T., Lam S.C., and Le Breton, G.C., “The P2Y12 Antagonists, 2-Methylthioadenosine 5’-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-independent Increase in cAMP Levels”,J Biol Chem. 2009 Jun;284(24):16108-17.
  4. Ting H.J., Murray W.J., and Khasawneh F.T., “Repurposing An Old Drug for A New Use: Glybenclamide Exerts Antiplatelet Activity By Interacting with the Thromboxane A2 Receptor”,Acta Pharmacol Sin. 2010 Feb;31(2):150-9
  5. Ting H.J., and Khasawneh F.T., “Platelet Function and Isoprostane Biology. Should Isoprostanes Be the Newest Member of the Orphan-Ligand Family?”,J Biomed Sci. 2010 Apr;17(1):24.
  6. Ting H.J., and Khasawneh F.T., “Glybenclamide: an Antidiabetic with in vivo Antithrombotic Activity”,Eur J Pharmacol. 2010 Dec;649(1-3):249-54.
  7. Gussin H.A.*, Khasawneh F.T.*, Xie A., Feng F., Memic A., Qian H., Le Breton, G.C., and Pepperberg D.R., “Subunit-Specific Polyclonal Antibody Targeting Human 1 GABAC Receptor”,Exp Eye Res. 2011 Jul;93(1):59-64.(*Authors contributed equally to this work)
  8. Ting H.J., Murad J.P., Espinosa E.V.P., and Khasawneh F.T., “Thromboxane A2 Receptor: Biology and Function of a Peculiar Receptor that Remains Resistant for Therapeutic Targeting”,J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):248-59.
  9. Zargarzadeh A., Jacob S., Klotz S.R., and Khasawneh F.T., “Clinical Pharmacists and Basic Scientists: Do Patients and Physicians Need this Collaboration?”,Int J Clin Pharm. 2011 Dec;33(6):886-94.
  10. Murad J.P., Ting H.J., Espinosa E.V.P., and Khasawneh F.T., “Characterization of the in vivo Antiplatelet Activity of the Antihypertensive Agent Losartan”,J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):308-14.
  11. Espinosa E.V.P., Murad J.P., and Khasawneh F.T., “Aspirin: Pharmacology and Clinical Applications”,Thrombosis. 2012 Nov;2012:173124.
  12. Guerra D., Morris D., Sipin A., Kung S., Franklin M., Gray D., Tanzil M., Guilford T., Khasawneh F.T., and Venketaraman V., “Glutathione and Adaptive Immune Responses Against Mycobacterium Tuberculosis Infection in Healthy and HIV Infected Individuals”, PLoS One. 2011 Dec;6(12):e28378.
  13. Murad J.P., Ting H.J., Espinosa E.V.P., and Khasawneh F.T., “The C-terminal Segment of the Second Extracellular Loop of the Thromboxane A2 Receptor Plays an Important Role in Platelet Aggregation”,Biochem Pharmacol. 2012 Jan;83(1):88-96.
  14. Espinosa E.V.P., Murad J.P., Ting H.J., and Khasawneh F.T., “Mouse Transient Potential Channel 6: Role in Hemostasis and Thrombogenesis”, Biochem Biophys Res Commun. 2012 Jan;417(2):853-6.
  15. Murad J.P., Espinosa E.V.P., Ting H.J., McClure D, and Khasawneh F.T., “A Novel Antibody Targeting the Ligand Binding Domain of the Thromboxane A2 Receptor Exhibits Antithrombotic Properties in vivo”,Biochem Biophys Res Commun. 2012 May;421(3):456-61.
  16. Murad J.P., Lin O.A., Espinosa E.V.P., and Khasawneh F.T., “Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions”, Curr Mol Med. 2013 Jan;13(1):165-78.
  17. Lin O.A., Karim Z.A., Vemana H., Espinosa E.V.P., and Khasawneh F.T., “The Antidepressant 5-HT2A Receptor Antagonists Pizotifen and Cyproheptadine Inhibit Serotonin-Enhanced Platelet Function”,PLoS One. 2014 Jan;9(1):e87026.
  18. Khasawneh F.T.,and Shankar G.S., “Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia,” Cardiol Res Pract. 2014 Feb;2014:273060.
  19. Karim Z.A., Vemana H., Alshbool F.Z., Lin O.A., Alshehri A.M., Javaherizadeh P., Espinosa E.V.P., and Khasawneh F.T., “Characterization of a Novel Function-Blocking Antibody Targeted Against The Platelet P2Y1 Receptor”,Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):637-44.
  20. Karim Z.A., Vemana H., and Khasawneh F.T., “MALT1-Ubiquitination Triggers Non-Genomic NF-B/IKK Signaling Upon Platelet Activation”, PLoS One. 2015 Mar;10(3):e0119363.
  21. Karim Z.A., Alshbool F.Z., Vemana H., Adhami N., Dhall S., Espinosa E.V.P., Martins-Green M., and Khasawneh F.T., “Third Hand Smoke: Impact on Hemostasis and Thrombogenesis”, J Cardiovasc J Cardiovasc Pharmacol. 2015 Aug;66(2):177-82.
  22. Vemana H., Karim Z.A., Conlon C., and Khasawneh F.T., “A Critical Role for the Transient Receptor Potential Channel Type 6 in Human Platelet Activation”, PLoS One. 2015 Apr;10(4):e0125764.
  23. Alshbool F.Z., Karim Z.A., Vemana H., Conlon C., Lin O.A., Khasawneh F.T., “The Regulator Of G-Protein Signaling 18 Regulates Platelet Aggregation, Hemostasis And Thrombosis”,Biochem Biophys Res Commun. 2015 Jul;462(4):378-82.
  24. Dhall S., Wijesinghe D.S., Karim Z.A., Castro A., Vemana HP, Khasawneh F.T., Chalfant, C.E, and Martins-Green, M., “Arachidonic acid-derived signaling lipids and functions in impaired healing”,Wound Repair Regen. 2015 Sep;23(5):644-56.
  25. Karim Z.A., Alshbool F.Z., Vemana H.P., Conlon C., Druey K.M., and Khasawneh, F.T., “CXCL12 regulates platelet activation via the regulator of G-protein signaling 16”, Biochim Biophys Acta. Biochim Biophys Acta. 2016 Feb;1863(2):314-21
  26. Dhall S.,Karim Z.A., Khasawneh, F.T., and Martins-Green M. “Platelet Hyperactivity in TNFSF14/LIGHT Knockout Mouse Model of Impaired Healing”, Adv Wound Care. 2016 Oct 1;5(10):421-431.
  27. Hensch N.R., Karim Z.A., Druey K.M., Tansey M.G., and Khasawneh F.T.,“RGS10 Negatively Regulates Platelet Activation and Thrombogenesis”. PLoS One. 2016 Nov 9;11(11):e0165984.

Published Abstracts (Peer-Reviewed)

  1. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein,” Proceedings of the 2006 International Conference, “Frontiers of Pharmacology and Toxicology”, Chemico-Biological Interactions,Vol. 161(3), 218-218, July 2006.
  2. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein.” Blood, Vol. 106(11), 996a-996a, November 2006.
  3. Khasawneh, F.T., Huang, J., Tiruppathi, C., and Le Breton, G.C., “Molecular Characterization of the 8-iso-PGF2α Interaction with the Thromboxane A2 Receptor and its Signaling Mechanisms in Human Platelets,” The FASEB Journal, Vol. 21(5), 569.10, April 2007.
  4. Srinivasan, S., Mir, F., Huang, J., Khasawneh, F.T., Huang, J., Lam, S., and Le Breton, G.C., “The adenosine-based P2Y12 antagonist, 2MeSAMP inhibits human plateletaggregation through a Gi-independent increase in platelet cAMP levels,” Arterioscler Thromb Vasc Biol, e-162 November 2008
  5. Ting, H.J, Khasawneh, F.T., “Glybenclamide Exhibits Thromboxane Receptor-Dependent Antiplatelet Effects”, Late-Breaking Abstract, The FASEB Journal. 2009; 23: LB385.
  6. Srinivasan, S., Mir, F., Huang, J., Khasawneh, F.T., Huang, J., Lam, S., and Le Breton, G.C., “ Cangrelor (ARC69931MX) produces global inhibition of human platelet function by increasing cAMP levels through a Gi-independent mechanism”,Late-Breaking Abstract, The FASEB Journal. 2009; 23: LB382.
  7. Ting, H.J, Khasawneh, F.T., “The Thromboxane A2 Receptor-Specific Antiplatelet Effects of Glybenclamide”, American Journal of Pharmaceutical Education. 2009; 73 (4) Article 57
  8. Ting, H.J, Shankar, G., and Khasawneh, F.T., “Investigation of the Anti‐Platelet Activity of a Novel Function‐Blocking Antibody Targeting the Human Thromboxane A2 Receptor Protein” platelet activation and biochemistry II, American Society of Hematology Meeting, December 7 2009.
  9. Ting, H.J, and Khasawneh, F.T., “Drug Rediscovery: Glybenclamide Exhibits Thromboxane Receptor-Dependent Antithrombotic Activity” platelet activation and biochemistry II, American Society ofHematology Meeting, December 7 2009.
  10. Murad, J.P., Ting, H.J, and Khasawneh, F.T., “The Transient Receptor-Potential Channel 6 Plays a Critical Role in Platelet Function”, 2010 American Society of Hematology Annual Meeting, Orlando, FL, December 6 2010.
  11. Murad, J.P., Ting, H.J., and Khasawneh, F.T., “The Second Extracellular Loop of the Thromboxane Receptor Plays an Important Role in Platelet Activation”, Experimental Biology 2011 Meeting, Washington DC, April 13 2011.
  12. Murad, J.P., Ting, H.J., and Khasawneh, F.T., “A Novel Mechanism for Calcium Entry Into Blood Platelets”, Late-Breaking Abstract, Experimental Biology 2011 Meeting; LB356, Washington DC, April 13 2011.
  13. Khasawneh, F.T., Law, A.V., Jackevicius, C., Murray, W.J., Pham, D.Q., Chow, M.S.S, Scott, J.D., Prabhu, S., and Robinson, D.C., School Poster (submitted by Assessment Committee) “Assessment of basic and clinical science content integration in the didactic curriculum using curricular mapping”, July 9, 2011, AACP Annual Meeting.
  14. Lin, O.A., Murad J.P., Espinosa E.V., and Khasawneh F.T., “Mapping of the G-Protein Coupling Domains of the Human Platelet Thromboxane A2 Receptor”, American Heart Association Scientific Sessions, Los Angeles, CA, November 5 2012
  15. Espinosa E.V., Lin, O.A., Murad J.P., and Khasawneh F.T., “The Transient Receptor-Potential Channel 6 Regulates Thromboxane A2 Receptor-Operated Calcium Entry and Plays a Critical Role in Platelet Function”, Arteriosclerosis, Thrombosis, Vascular Biology Meeting, Lake Buena Vista, FL, May 1-3 2013
  16. Vemana H.P., Karim Z.A., Lin, O.A., and Khasawneh F.T., ”Regulation of Platelet Activation by Transient Receptor Potential Channel 6”, Thrombosis & Hemostasis Summit of North American 2014, Chicago, IL, April 10-12 2014
  17. Karim Z.A., Venkatesan N., Ting, H.J,Betageri G., andKhasawneh, F.T., “A Novel Parenteral Formulation For the Antiplatelet Agent Clopidogrel”, Late-Breaking Abstract, The FASEB Journal. 2016; LB532.
Editorials
  1. Khasawneh, F.T., and Karim, Z.A., “Lipid Raft and Platelet SNARE Machinery”, J Glycomics Lipidomics 2014, 4: e119.

Abstractsand Posters

  1. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Identification of the Amino Acids Involved in Ligand Binding to the Human Thromboxane A2 Receptor Protein,” Abstract, 10th Biennial Midwest Platelet Conference, Milwaukee, Wisconsin, October 8-10, 2004.
  2. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Identification of the Amino Acids Mediating Thromboxane A2 Receptor-Ligand Coordination,” Poster Presentation, The 36th Annual Midwest Student Biomedical Research Forum, University of Nebraska Medical Center, Omaha, Nebraska, February 18-19, 2005.
  3. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Identification of the Amino Acids Mediating Thromboxane A2 Receptor-Ligand Coordination,” Poster Presentation, 18th Annual Scientific Meeting of the Great Lakes Chapter, American Society for Pharmacology and Experimental Therapeutics, Midwestern University, Downers Grove, Illinois, June 17, 2005.
  4. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Amino Acids Participating in the Human Thromboxane A2 Receptor Agonist and Antagonist Interaction Process,” Poster Presentation, Department of Pharmacology Annual Retreat, Lake Geneva, Wisconsin, September 29-30, 2005.
  5. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Differential Mapping of The Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein,” Poster Presentation, The 46th Annual meeting of the American Society of Hematology, Atlanta, Georgia, December 4-7, 2005.
  6. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Amino Acids Participating in the Human Thromboxane A2 Receptor Agonist and Antagonist Interaction Process,” Poster Presentation, College of Medicine Student Medical Research Forum, University of Illinois at Chicago, Chicago, February 1, 2006.
  7. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Differential Mapping of The Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein,” Poster Presentation, 19th Annual Scientific Meeting of the Great Lakes Chapter-American Society for Pharmacology and Experimental Therapeutics, University of Illinois at Chicago, Chicago, Illinois, June 9, 2006.
  8. Khasawneh, F.T., Huang, J., Turek, J., and Le Breton, G.C., “Differential Mapping of The Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein,” Poster Presentation, 2006 International Conference, Frontiers of Pharmacology and Toxicology, Chicago, Illinois, August 28-31, 2006.
  9. Khasawneh, F. T., Huang, J., Turek, J., and Le Breton, G.C., “Characterizing the Coordination Forces Between the Human Thromboxane A2 Receptor and its Ligand Pharmacophores,” 11th Biennial Midwest Platelet Conference, Chicago, Illinois, October 5-8, 2006.
  10. Khasawneh, F.T., Huang, J., Tiruppathi, C., and Le Breton, G.C., “8-iso-PGF2α is a Potent Agonist for the Human Thromboxane A2 Receptor with a Unique Ligand Binding Profile,” 11th Biennial Midwest Platelet Conference, Chicago, Illinois, October 5-8, 2006.
  11. Khasawneh, F.T., Huang, J., Tiruppathi, C., and Le Breton, G.C., “Molecular Characterization of the 8-iso-PGF2α Interaction with the Human Thromboxane A2 Receptor and its Signaling Mechanisms in Human Platelets,” Experimental Biology Annual Meeting, Washington, DC, April 28–May 2, 2007.
  12. Khasawneh, F.T., Huang, J., Tiruppathi, C., and Le Breton, G.C., “Evidence for the Presence of a Novel Gs-coupled Isoprostane Receptor in Human Platelets,” Poster Presentation, College of Medicine Student Medical Research Forum, University of Illinois at Chicago, Chicago, February 7, 2007.
  13. Khasawneh, F.T. and Le Breton, G.C., “Evidence for the Presence of a Novel Gs-coupled Isoprostane receptor in Human Platelets,” Poster Presentation, The 38th Annual Midwest Student Biomedical Research Forum, University of Nebraska Medical Center, Omaha, Nebraska, February 23-24, 2006.
  14. Khasawneh, F.T. and Le Breton, G.C., “Evidence for the Presence of a Novel Gs-coupled Isoprostane Receptor in Human Platelets,” The 20th Annual Scientific Meeting of the Great Lakes Chapter of the American Society for Pharmacology and Experimental Therapeutics, Rosalind Franklin University, North Chicago, Illinois, June 8, 2007.
  15. Gussin, H.A., Khasawneh, F.T., Xie, A., Qian, H., Le Breton, G.C., Pepperberg, D.R., “Characterization of a Novel Polyclonal Anti Human 1 GABAC Antibody, “ The 2008 Annual Meeting of The Association for Research in vision and Ophthalmology, Fort Lauderdale, Florida, April 27- May 1, 2008.
  16. Srinivasan, S., Mir, F., Huang, J., Khasawneh, F.T., Huang, J., Lam, S., and Le Breton, G.C., “The adenosine-based P2Y12 antagonist, 2MeSAMP inhibits human plateletaggregation through a Gi-independent increase in platelet cAMP levels,” 12th Biennial Midwest Platelet Conference, Lexington, Kentucky, October 2-4, 2008.
  17. Ting, H.J, and Khasawneh, F.T., “A Novel Antagonist for the Thromboxane A2 Receptor”. EB 2010 Meeting, April 25, 2010
  18. Ting, H.J, and Khasawneh, F.T., “Drug Rediscovery: Glybenclamide Exhibits Thromboxane Receptor Dependent Antithrombotic Activity”. EB 2010 Meeting, April 25, 2010
  1. Murad, J.P., Ting, H.J, and Khasawneh, F.T., “A Novel Antagonist for the Thromboxane A2 Receptor”. Tobacco-Related Disease Research Symposium, University of California Riverside, October 29, 2010
  2. Murad, J.P., Ting, H.J, and Khasawneh, F.T., “The Transient Receptor-Potential Channel 6 Plays a Critical Role in Platelet Function”.Western University Research Day, Western University of Health Sciences, March 25, 2011.
  3. Morris, D., Franklin, M., Ho, H., Khurasany, M., Guilford, T., Khasawneh, F.T., and Venketaraman, V. “Unveiling the Mechanisms for Decreased GSH in Individuals With HIV Infection”. Southern California Academy of Sciences Annual Meeting, May 6-7, 2011
  4. Murad J.P., Espinosa E.V., Ting H.J., and Khasawneh F.T., “Targeting the Ligand-Binding Domain of the Platelet Thromboxane A2 receptor for Therapeutic Interventions” Linking Tobacco Control Research and Practice for a Healthier California Meeting, Tobacco-Related Disease Research Program, University of California Office of the President, Sacramento CA, April 10-12, 2012
  5. Paez Espinosa, EV., Murad, J.P., Ting, H.J., and Khasawneh F.T., “Transient Receptor Potential Channel 6: Role in Hemostasis and Thrombogenesis”, Experimental Biology 2012 Meeting, San Diego, CA, April 25 2012
  6. Murad J.P., Espinosa E.V., Ting H.J., and Khasawneh F.T., “A Novel Antithrombotic Agent Targeting the Human Thromboxane A2 Receptor”, Experimental Biology 2012 Meeting, San Diego, CA, April 25 2012
  7. Murad J.P., Espinosa E.V., Ting H.J., and Khasawneh F.T., “Targeting the Ligand-Binding Domain of the Platelet Thromboxane A2 receptor for Therapeutic Interventions”, 14th Biennial Midwest Platelet Conference, Cleveland, Ohio, October 18-19, 2012.
  8. Lin, O.A, Espinosa E.V., and Khasawneh F.T., “The 5-HT2A Receptor Antagonists Pizotifen and Cyproheptadine Inhibit Serotonin-enhanced Platelet Function”, Experimental Biology 2013 Meeting, Boston, MA, April 23 2013
  9. Vemana H.P., Karim Z.A., Lin, O.A., and Khasawneh F.T.,”A Critical Role for the Transient Receptor Potential Channel Type 6 in Human Platelet Activation”, Hemostasis Gordon Research Conference, Waterville Valley, NH, July 27-August 1 2014.
  10. Alshehri A.M., Karim Z.A., Vemana H.P., Lin, O.A., and Khasawneh F.T.,”A Novel Function Blocking Antibody Targeting the ADP P2Y1 Receptor Protein”, College of Pharmacy Poster Day, Western University of Health Sciences, Pomona, CA, May 8 2014.
  11. Karim Z.A., Espinosa E.V.P., Lin O.A., Vemana H.P., Murad J.P., andKhasawneh F.T., “The Transient Receptor-Potential Channel 6: Modulation of Platelet Function By Regulation of the Thromboxane A2 Receptor-Operated Calcium Entry”, 15th Biennial Midwest Platelet Conference, Chicago, IL, October 8-10, 2014.
  12. Khasawneh F.T., Vemana H.P., and Karim, Z.A. “A Novel MALT1-Ubiquitination Pathway Regulates Non-Genomic NF-B/IKK Signaling in Platelets”, 15th Biennial Midwest Platelet Conference, Chicago, IL, October 8-10, 2014.
  13. Karim Z.A., Vemana H.P., Lin O.A., Alshehri A.M., Javaherizadeh P., Espinosa E.V.P., Murad J.P., and Khasawneh F.T., “Characterization of a Novel Function-Blocking Antibody Targeted Against The Platelet P2Y1 Receptor”, 15th Biennial Midwest Platelet Conference, Chicago, IL, October 8-10, 2014.
  14. Vemana H.P., Karim Z.A., Conlon C., and Khasawneh F.T.,”A New Player In Platelet Function”, Experimental Biology 2015 Meeting, Boston, MA, March 29 2015
  1. Karim Z.A., Alshbool F.Z., Vemana H.P., Adhami N., Dhall S., Lin O.A., Espinosa E.V.P, Martins-Green M., and Khasawneh F.T. ”Third Hand Smoke: Impact on Hemostasis and Thrombogenesis”. Cell Biology of Megakaryocytes & Platelets, Gordon Research Conference, April 19-24 2015,Lucca (Barga), Italy.
  1. Karim Z.A., Alshbool F.Z., Vemana H.P., Adhami N., Dhall S., Lin O.A., Espinosa E.V.P, Martins-Green M., and Khasawneh F.T., “Third Hand Smoke: Impact on Hemostasis and Thrombogenesis” Translational Nicotine Research Group Symposium, June 26 2015, University of California Los Angeles, Los Angeles, CA.
  2. HenschN.R., Karim Z.A. and Khasawneh F.T.,”Antibody Targeted Against P2Y12 Receptor Reduces Platelet Activity In vitro and In vivo”, Experimental Biology 2016 Meeting, San Diego, CA, April 4 2016.
  3. Karim Z.A.,Lin O.A., and Khasawneh F.T.,”The First Intracellular Loop Regulates The Platelet Thromboxane A2 Receptor-Gq-Dependent Signaling And Function”, Experimental Biology 2016 Meeting, San Diego, CA, April 4 2016.
  4. Karim Z.A., Venkatesan N., Hensch, N.R., Ting, H.J,Betageri G., andKhasawneh, F.T., “Characterization of a Liposome-Based Formulation for Clopidogrel”, Hemostasis Gordon Research Conference, Stoweflake, VT, July 24 - July 29 2016.
  5. Karim Z.A., Hensch, N.R., andKhasawneh, F.T., “Essential role for IB Kinase  in remodeling CARMA1/Bcl10/MALT1 complexes in activated platelets”, Hemostasis Gordon Research Conference, Stoweflake,VT, July 24 - July 29 2016.

Oral/Invited Presentations

  1. Khasawneh, F.T. and Le Breton, G.C., “Identification of the Amino Acids Involved in Ligand Binding to the Human Thromboxane A2 Receptor Protein,” 10th Biennial Midwest Platelet Conference, Milwaukee, Wisconsin, October 8-10, 2004.
  2. Khasawneh, F.T. and Le Breton, G.C., “Differential Mapping of The Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein,” The 47th Annual National Student Research Forum, University of Texas Medical Branch, Galveston, Texas, April 27-28, 2006.
  3. Khasawneh, F.T. and Le Breton, G.C., “Molecular Characterization ofIsoprostanes Signaling and Biological Effects: Evidence for the Presence of a Novel Gs-coupled Receptor in Human Platelets,” The 48th Annual National Student Research Forum, University of Texas Medical Branch, Galveston, Texas, April 26-27, 2007.
  4. Khasawneh, F.T., Huang, J., Tiruppathi, C., and Le Breton, G.C., “Molecular Characterization of the 8-iso-PGF2α Interaction with the Human Thromboxane A2 Receptor and its Signaling Mechanisms in Human Platelets,” American Society for Pharmacology and Experimental Therapeutics, Cardiovascular Division Best Abstract Competition Forum, EB 2007, Washington, DC, April 30, 2007.
  5. Ting, H.J, and Khasawneh, F.T., “Drug Rediscovery: Glybenclamide Exhibits Thromboxane Receptor Dependent Antithrombotic Activity” Cardiovascular III, 2010 Western Regional Meeting, January 2010.
  6. Murad J.P., Espinosa E.V., Ting H.J., Khasawneh F.T., “A Novel Antithrombotic Agent Targeting the Human Thromboxane A2 Receptor”, Cardiovascular Pharmacology Division Trainee Showcase, Experimental Biology 2012 Meeting, San Diego, CA, April 24 2012
  7. Khasawneh F.T., “Characterization of a Novel Antagonist for the Human Platelet Thromboxane A2 Receptor”, 3rd International Conference on Biomarkers & Clinical Research, Las Vegas, Nevada, July 2-4 2012.
  8. Khasawneh F.T., “Targeting the Ligand-Binding Domain of the Platelet Thromboxane A2 receptor for Therapeutic Interventions”, 14th Biennial Midwest Platelet Conference, Cleveland, Ohio, October 18-19, 2012.
  9. Khasawneh F.T., “The Transient Receptor-Potential Channel 6 Regulates Thromboxane A2 Receptor-Operated Calcium Entry and Plays a Critical Role in Platelet Function”, Arteriosclerosis, Thrombosis, and Vascular Biology 2013 Meeting, Lake Buena Vista, Florida (May 1-3, 2013).
  10. Khasawneh F.T., “The Transient Receptor-Potential Channel 6: Modulation of Platelet Function By Regulation of the Thromboxane A2 Receptor-Operated Calcium Entry”, 15th Biennial Midwest Platelet Conference, Chicago, IL, October 8-10, 2014.
  11. Khasawneh F.T., “Grant Writing 101- Part I”, A Faculty Development Activity Organized by the Faculty Orientation and Development Committee. College of Pharmacy, Western University of Health Sciences, February 11, 2016.

Book Chapters